Ondine Biomedical Inc. (AIM:OBI)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 62.35M +52.1% |
| Revenue (ttm) | 1.18M +34.8% |
| Net Income | -12.79M |
| EPS | -0.03 |
| Shares Out | 519.55M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 13,492 |
| Average Volume | 552,717 |
| Open | 12.50 |
| Previous Close | 12.00 |
| Day's Range | 11.50 - 13.00 |
| 52-Week Range | 7.50 - 18.50 |
| Beta | 0.27 |
| RSI | 64.06 |
| Earnings Date | May 21, 2026 |
About Ondine Biomedical
Ondine Biomedical Inc., a life-sciences company, engages in the development and commercialization of antimicrobial therapies in Canada and internationally. Its primary product is Steriwave, which enables rapid elimination of pathogens associated with healthcare-associated infections. In addition, the company offers a pipeline of products for various indications, including burns, ventilator tube, and sinus; and serious and chronic wounds, chronic sinusitis, ventilator-associated pneumonia VAP, and central line bloodstream infections, as well as ... [Read more]
Financial Performance
In 2024, Ondine Biomedical's revenue was 2.05 million, an increase of 70.32% compared to the previous year's 1.20 million. Losses were -19.10 million, 32.5% more than in 2023.
Financial numbers in CAD Financial StatementsNews
Ondine Biomedical Earnings Call Transcript: H1 2025
Strong revenue and margin growth were achieved in H1 2025, with expanding adoption in Canada, the UK, and Europe. Strategic partnerships and a robust product pipeline support future growth, while recent funding secures operations through Q2 2026.
Ondine Biomedical Earnings Call Transcript: Q4 2024
2024 saw 70% revenue growth, improved gross margins, and expanded hospital adoption, driven by new partnerships and product launches. Cash runway extends into early Q4 2025, with key clinical studies progressing and strategic funding secured.
Ondine Biomedical's US $11M Fundraise Enables a Q4 2024 Start of Its Pivotal Phase 3 US Trial
VANCOUVER, British Columbia--(BUSINESS WIRE)--Ondine Biomedical announces that it is accelerating its US Phase 3 trial following its recent successful raise of Cdn $16 million (£9m, US $11m).
Ondine Biomedical Earnings Call Transcript: H1 2024
Revenue doubled year-over-year, driven by rapid hospital adoption and a major partnership with Mölnlycke. The company is launching a pivotal US phase 3 trial and expanding into ICU indications, while maintaining strong margins and operational efficiency.
Ondine Biomedical Earnings Call Transcript: H2 2023
Revenues nearly doubled in 2023 with exponential hospital adoption and improved gross margins. U.S. phase III study is set for 2024, with commercialization expected in 2026, while international growth and operational scaling continue.